Home⇛The PCMC Journal⇛vol. 15 no. 1 (2019)

Immediate rescue reversal of rocuronium-induced intense neuromuscular blockade using sugammadex in pediatric surgical patients

Joanne C. Altamera-Remedios | Pamela Joy G. Lim-Lopez | Janette T. Fusileo-Pascual | Teresita A. Batanes

Discipline: medicine by specialism

 

Abstract:

BACKGROUND: The dose of Sugammadex for rescue reversal of intense neuromuscular block has not been studied in children. The only recommended dose of Sugammadex in children is 2mg/kg to reverse a shallow block. OBJECTIVES: To assess the efficacy and safety of Sugammadex 2mg/kg and 4mg/kg as immediate rescue reversal of intense rocuronium-induced neuromuscular block in pediatric patients METHODS: 80 children, aged 2 to 11 years old, requiring general anesthesia were enrolled in this randomized prospective study. Group 1 given Sugammadex 2mg/kg (40 subjects) while Group 2 received Sugammadex 4mg/kg (40 subjects), at the end of the procedure if PTC=0. The Recovery Time was recorded (TOF ratio ≥0.9) (Primary Outcome). Discharge readiness in the PACU was assessed using Modified Aldrete Scale (Secondary Outcome). Monitoring of adverse effects in the ward continued until 24 hours postoperatively. RESULTS: There were significantly more patients in the Sugammadex 4mg/kg that had a recovery time of ≤2min as compared to those given Sugammadex 2mg/kg (p=0.012). There was no significant difference in the Aldrete score between the two groups (p=0.2776). All patients achieved a very satisfactory discharge score in the PACU. The adverse effects experienced by the patients in the two doses of Sugammadex in the PACU and up to 24 hours postoperatively were not significantly different. CONCLUSION: Sugammadex 4mg/kg can be considered safe and effective as an immediate reversal agent for rocuronium-induced intense neuromuscular blockade in children. RECOMMENDATION: Clinicians should identify if Sugammadex 6mg/kg, compared with 4mg/kg, would translate to a shorter Recovery time to a TOF ratio of 0.9. The time from TOF ratio of 0.9 to the time of extubation should be measured to increase the efficacy and safety assessment of Sugammadex in this age group.



References:

  1. Jeff Harless, Ramesh Ramaiah, and Sanjay M Bhananker. Pediatric airway management. Int J Crit Illn Inj Sci. 2014 Jan-Mar; 4(1): 65–70.
  2. Pennsylvania Patient Safety Authority. Management of Unanticipated Difficult Intubation. Vol. 7, No. 4 - December 2010.
  3. J. Adam Law et al. The difficult airway with recommendations for management – Part 1 – Difficult tracheal intubation in an unconscious/induced patient. Can J Anaesth. 2013; 60(11): 1089–1118.
  4. Curtis R, Lomax S, Patel B. Use of sugammadex in a ‘can’t intubate, can’t ventilate’ situation. Br J Anaesth. 2012;108(4):612-4.
  5. Bhananker SM et al. Anesthesia-related cardiac arrest in children: update from the Pediatric Perioperative Cardiac Arrest Registry. Anesth Analg. 2007;105:344–350.
  6. Murat I, Constant I, Maud‘huy H. Perioperative anaesthetic morbidity in children: 24,165 anaesthetics over 30 months. Paediatr Anaesth. 2004;14:158–166.
  7. Heinrich S et al. Incidence and predictors of difficult laryngoscopy in 11,219 pediatric anesthesia procedures. Paediatr Anaesth. 2012;22:729–736.
  8. Bom A. The Discovery and Preclinical Development of Sugammadex. MSD Research Institute, Newhouse, Scotland. 2010.
  9. Ezri T et al. Sugammadex: An Update. J Crit Care Med 2016;2(1):16-21.
  10. Mendonca C. Sugammadex to rescue a ‘can’t ventilate’ scenario in an anticipated difficult intubation. Anaesthesia. 2013;68:795-9.
  11. Kasai M et al. Reversibility of rocuronium-induced neuromuscular blockade with sugammadex in neonates.
  12. Meretoja O. Neuromuscular block and reversal strategies in children. Pediatr Anesth 2010;20:591–604.
  13. Plaud B et al. Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in pediatric and adult surgical patients. Anesthesiology 2009;110:284–94.
  14. Benigni A et al. Efficacy and safety of sugammadex 4 mg/kg in infants and children: a case series.
  15. Merck & Co. BRIDION: EPAR – Product Information Annex I. European Medicines Agency, 2013.
  16. Fuchs-Buder T. Neuromuscular Block Management and Sugammadex: An Update. 2010.
  17. Pühringer FK et al. Reversal of high-dose rocuronium-induced blockade by sugammadex: phase II trial. Anesthesiology 2008;109:188–97.
  18. Suy K et al. Effective reversal of moderate rocuronium or vecuronium block with sugammadex. Anesthesiology 2007;106:283–8.
  19. Copp MV, Barrett TF. Sugammadex: Role in anaesthetic practice and patient safety. World J Anesthesiol. Aug 2015.
  20. Caldwell J. Sugammadex: past, present and future. Adv Anaesth 2011;29:19-27.
  21. Lobaz S et al. Safety and efficacy of Sugammadex for neuromuscular blockade reversal. Clin Med Insights: Therapeutics 2014;6:1–14.
  22. Osmer C et al. Comparative use of muscle relaxants and reversal in France, Germany, and Great Britain. Eur J Anaesthesiol 1996;13:389–99.
  23. Naguib M. Pharmacology of muscle relaxants and antagonists. In: Miller RD, Anaesthesia. 6th ed. 2006. p. 481–572.
  24. Barrow MEH, Johnson JK. Anticholinesterase and anticurare effects of cholinesterase inhibitors. Br J Anaesth 1996;38:420–31.
  25. Feldman A, Fauvel N. Recovery from a neuromuscular block. In: Pollard B, Applied Neuromuscular Pharmacology. 1994;107–22.
  26. van den Broek L et al. Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol Suppl 1994;9:128–32.
  27. Kirkegaard-Nielsen H et al. Optimum time for neostigmine reversal of atracurium block. Can J Anaesth 1996;43:932–8.
  28. Bevan JC et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg 1999;89:333–9.
  29. Meretoja OA, Gebert R. Postoperative neuromuscular block following atracurium or alcuronium in children. Can J Anaesth 1990;37:743–746.
  30. Bartkowski RR. Incomplete reversal of pancuronium block by neostigmine, pyridostigmine, and edrophonium. Anesth Analg 1987;66:594–598.
  31. Beemer GH et al. Determinants of reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991;66:469–475.
  32. Cronnelly R et al. Edrophonium: duration and atropine requirement during halothane anesthesia. Anesthesiology 1982;57:261–266.
  33. Kirkegaard-Nielsen H et al. Time to peak neostigmine effect at antagonism of atracurium or vecuronium. J Clin Anesth 1995;7:635–639.
  34. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009;103:115–129.
  35. Barber HE et al. Pharmacokinetics and twitch tension effects of anticholinesterases. Br J Pharmacol 1979;66:525–530.
  36. Ansermino JM et al. Acceleromyography improves detection of residual neuromuscular blockade in children. Can J Anaesth 1996;43:589–594.
  37. Murphy GS et al. Acceleromyographic monitoring reduces residual block and respiratory events. Anesthesiology 2008;109:389–398.
  38. Pino RM. Residual neuromuscular blockade: a persistent clinical problem. Int Anesthesiol Clin 2006;44:77–90.
  39. Bevan DR, Smith CE, Donati F. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Anesthesiology 1988;69:272–276.
  40. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007;98:302–316.
  41. Hunter JM. Is it always necessary to antagonize residual neuromuscular block? Do children differ from adults? Br J Anaesth 1996;77:707–709.
  42. Stefan Josef Schaller, Heidrun Fink. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evidence, 2013.
  43. R. Kevin Jones et al. Reversal of Profound Rocuronium-induced Blockade with Sugammadex: A Randomized Comparison with Neostigmine. Anesthesiology 2008;109:816–24.
  44. Bom A et al. A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem 2002;114:276–80.
  45. Adam JM et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002;45:1806–1816.
  46. Bom A, Clark JK, Palin R. New approaches to reversal of neuromuscular block. Curr Opin Drug Discov Devel 2002;5:793–800.
  47. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care 2009;24:29–35.
  48. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006;97:123–126.
  49. Abrishami A et al. Sugammadex for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev 2009;4:CD007362.
  50. Ploeger BA et al. Pharmacokinetic–pharmacodynamic model for reversal of neuromuscular blockade by sugammadex. Anesthesiology 2009;110:95–105.
  51. Sparr HJ et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 2007;106:935–943.
  52. Bom A, Hope F. Sugammadex restores spontaneous respiration after profound blockade with rocuronium (abstract). Anesthesiology 2008;109:A356.
  53. Akha AS et al. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin. 2010;28(4):691–708.
  54. Paton L, Gupta S, Blacoe D. Successful use of sugammadex in a ‘can’t ventilate’ scenario. Anaesthesia. 2013 Aug;68(8):861-4.
  55. Bogumiła Wołoszczuk-Gębicka1, Lidia Zawadzka-Głos2, Jerzy Lenarczyk1, Bożena
    Dorota Sitkowska1, Iwona Rzewnicka3. Department of Paediatric Anaesthesiology and Intensive Therapy, Medical University of Warsaw, Poland; Department of Paediatric Otolaryngology, Medical University of Warsaw, Poland; Department of Paediatric Surgery and Urology, Medical University of Warsaw, Poland. Two cases of the “cannot ventilate, cannot intubate” scenario in children in view of recent recommendations. Anaesthesiology Intensive Therapy. 2014;46(2):88–91.
  56. Partownavid P, Romito BT, Ching W, Berry AA, Barkulis CT, Nguyen KP, Jahr JS. Sugammadex: A comprehensive review of the published human science, including renal studies. Am J Ther. 2015;22:298-317.
  57. Staikou C, Stamelos M, Stavroulakis E. Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity. Br J Anaesth. 2014;112:217-230.
  58. de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther. 2012;50(8):595–604.
  59. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014;69:1251-1257. [PMID: 24848211 DOI: 10.1111/anae.12736].
  60. Crisafi. Clinical evaluation of sugammadex: efficacy and safety. Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) Meeting. November 6, 2016.
  61. Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth. 2010;105(5):568–575.
  62. eMC. Bridion 100 mg/ml. Sugammadex. http://www.medicines.org.uk/EMC/medicine/21299/SPC/Bridion+100+mg+ml+solution+for+injection/. Updated October 25, 2013.
  63. Kam PJ, Heuvel MW, Grobara P, Zwiers A, Jadoul JL, de Clerck E, Ramael S, Peeters PA. Flucloxacillin and diclofenac do not cause recurrence of neuromuscular blockade after reversal with sugammadex. Clin Drug Investig. 2012;32(3):203–212.
  64. http://www.ema.europa.eu/humandocs/PDFs/EPAR/bridion/emea-combined-h885en.pdf. Accessed 26 May 2010.
  65. Padmaja, Mantha. Monitoring of neuromuscular junction. Indian J Anaesth. 2002;46(4):279-288.
  66. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology. 1979;50:539-541.
  67. Caldwell JE, Miller RD. Clinical implications of sugammadex. Anaesthesia. 2009;64(Suppl. 1):66–72.
  68. Bragg P, Fisher DM, Shi J, Donati F, Meistelman C, Lau M, Sheiner LB. Comparison of twitch depression of the adductor pollicis and the respiratory muscles: pharmacodynamic modeling without plasma concentrations. Anesthesiology. 1994;80:310–319.
  69. Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis oculi, and adductor pollicis muscles. Anesthesiology. 1990;73:870–875.
  70. Wright PM, Caldwell JE, Miller RD. Onset and duration of rocuronium and succinylcholine at the adductor pollicis and laryngeal adductor muscles in anesthetized humans. Anesthesiology. 1994;81:1110–1115.
  71. Cantineau JP, Porte F, d’Honneur G, Duvaldestin P. Neuromuscular effects of rocuronium on the diaphragm and adductor pollicis muscles in anesthetized patients. Anesthesiology. 1994;81:585–590.
  72. Bonsu AK, Viby-Mogensen J, Fernando PU, Muchhal K, Tamilarasan A, Lambourne A. Relationship of post-tetanic count and train-of-four response during intense neuromuscular blockade caused by atracurium. Br J Anaesth. 1987;59:1089–1092.
  73. Engbaek J, Ostergaard D, Skovgaard LT, Viby-Mogensen J. Reversal of intense neuromuscular blockade following infusion of atracurium. Anesthesiology. 1990;72:803–806.
  74. Eriksson LI, Lennmarken C, Staun P, Viby-Mogensen J. Use of post-tetanic count in assessment of a repetitive vecuronium-induced neuromuscular block. Br J Anaesth. 1990;65:487–493.
  75. Ali HH, Utting JE, Gray C. Stimulus frequency in the detection of neuromuscular block in humans. Br J Anaesth. 1970;42:967–978.
  76. McGrath C, Hunter J. Monitoring of neuromuscular block. Contin Educ Anaesth Crit Care Pain. 2006;6(1):1–5.
  77. Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekberg O, Kuylenstierna R. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology. 1997;87:1035–1043.
  78. Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose–effect relationship for neostigmine. Anesthesiology. 2010;112:34–40.
  79. Viby-Mogensen. Neuromuscular monitoring. In: Miller RD, ed. Anesthesia. 5th ed. New York: Churchill Livingstone; 2000:1351–1366.
  80. Madsen MV, Scheppan S, Kissmeyer P, Mørk E, Rosenberg J, Gätke MR. Neuromuscular blockade for improvement of surgical conditions during laparotomy: protocol for a randomised study. Dan Med J. 2015;62(10):A5139.
  81. Hemmerling TM, Donati F. Neuromuscular blockade at the larynx, the diaphragm and the corrugator supercilii muscle: a review. Can J Anaesth. 2003;50:779–794.
  82. Kirov K, Motamed C, Ndoko SK, Dhonneur G. TOF count at corrugator supercilii reflects abdominal muscles relaxation better than at adductor pollicis. Br J Anaesth. 2007;98:611–614.
  83. Dhonneur G, Kirov K, Motamed C, Amathieu R, Kamoun W, Slavov V, Ndoko SK. Post-tetanic count at adductor pollicis is a better indicator of early diaphragmatic recovery than train-of-four count at corrugator supercilii. Br J Anaesth. 2007;99:376–379.
  84. Fernando PU, Viby-Mogensen J, Bonsu AK, et al. Relationship between post-tetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1987;31:593–596.
  85. Marín PCE, Engelhardt T. Algorithm for difficult airway management in pediatrics. Rev Colomb Anestesiol. 2014;42:325–334.
  86. Jimenez N, Posner KL, Cheney FW, Caplan RA, Lee LA, Domino KB. An update on pediatric anesthesia liability: a closed claims analysis. Anesth Analg. 2007;105:147–153.
  87. Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. Part I: Anaesthesia. Br J Anaesth. 2011;106:617–631.
  88. Lee CM. Train-of-4 quantitation of competitive neuromuscular block. Anesth Analg. 1975;54:649–653.
  89. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for industry – clinical safety data management: definitions and standards for expedited reporting. August 25, 2007. FDA Center for Drug Evaluation and Research.
  90. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm
  91. Godai K, Hasegawa-Moriyama M, Kuniyoshi T, Kakoi T, Ikoma K, Isowaki S, Matsunaga A, Kanmura Y. Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth. 2012;109(2):216–218. doi:10.1093/bja/aes137.
  92. Sarı S, Taşdemir B, Sözkısacık S, Gürsoy F. Side effects of sugammadex use in pediatric patients. J Clin Exp Investig. 2013;4(3):265–268. https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system
  93. Godoy ML, Pino PA, Córdova GL, Carrasco JA, Castillo AM. Sedation and analgesia in children undergoing invasive procedures. Arch Argent Pediatr. 2013;111(1):22–28.
  94. Pedersen T, Viby-Mogensen J, Bang U, OIsen NV, Jensen E, Engbaek J. Does perioperative tactile evaluation of the train-of-four response influence the frequency of postoperative residual neuromuscular blockade? Anesthesiology. 1990;73:835–839.
  95. http://sketchymedicine.com/wp-content/uploads/2013/11/nmb1.png
  96. http://www.scielo.br/img/revistas/rba/v62n3/en_a16chart01m.jpg
  97. Abramson NS, Safar P; Brain Resuscitation Clinical Trial I Study Group. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. N Engl J Med. 1986;314:397–403.
  98. Hussain N, Mendonca C. Unanticipated difficult airway: can sugammadex rescue can’t intubate can’t ventilate (CICV) scenario? J Anesth Clin Res. 2012;3:e109. doi:10.4172/2155-6148.1000e109.
  99. Kasai M, Igarashi C, Miyazawa N, Yamamoto S, Suzuki T. Reversibility of rocuronium-induced profound neuromuscular blockade with sugammadex in neonates. Tokyo Metropolitan Children’s Medical Center, Department of Anesthesiology; Nihon University School of Medicine, Department of Anesthesiology.
  100. American Society of Anesthesiologists. Practice guidelines for management of the difficult airway: an updated report. Anesthesiology. 2003;98:1269–1277.
  101. Resuscitation Council. Anaphylaxis algorithm. March 2008. www.resus.org.uk
  102. American Heart Association. CPR & ECC guidelines: pediatric bradycardia with a pulse and poor perfusion algorithm. 2015.
  103. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Østergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent. Sugammadex: A dose-finding and safety study. Anesthesiology. 2006;104:667–674.
  104. Cope TM, Hunter JM. Selecting neuromuscular blocking drugs for elderly patients. Drugs Aging. 2003;20:125–140.
  105. Kara T, Ozbagriacik O, Turk HS, Isil CT, Gokuc O, Unsal O, Seyhan E, Oba S. Sugammadex versus neostigmine in pediatric patients: a prospective randomized study. Rev Bras Anestesiol. 2014;64(6):400–405. doi:10.1016/j.bjan.2014.03.001.
  106. Donati F, Bevan DR. Neuromuscular blocking agents. Available from: http://faculty.washington.edu/ramaiahr/BARASH.pdf
  107. Hartman ME, Cheifetz IM. Pediatric emergencies and resuscitation. In: Kliegman RM, Stanton BF, Geme JW III, Schor NF, Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Elsevier; 2011. p. 280.
  108. Zwer F. Factors affecting neuromuscular transmission and block. J Anesth Crit Care Open Access. 2016;6(1):00216. doi:10.15406/jaccoa.2016.06.00216.

Tools


Copyright © 2025  KITE Digital Educational Solutions |  Exclusively distributed by CE-Logic